Boston Scientific (BSX) Stock Price
Boston Scientific Price
Revenue has compounded at 5.1% per year over the past 19 years to 20.07 B USD. Earnings per share have grown at 14.1% per year over the last 14 years. Boston Scientific's net margin stands at 14.4%, up from 8.7% several years earlier. Analysts set a median price target of 63.50 USD, implying 49.1% above the current price. Of 38 analysts, 30 rate the stock a buy — an overall Buy consensus.
Boston Scientific stock price
Boston Scientific business model & stock analysis
Frequently asked questions about Boston Scientific
The main competitors of Boston Scientific Corp in the market include Medtronic, Johnson & Johnson, Abbott Laboratories, and Edwards Lifesciences.
Boston Scientific Corp is a global medical technology company. Its business model revolves around developing innovative medical solutions that enhance patient care and healthcare outcomes. Boston Scientific Corp manufactures and markets a broad range of medical devices used in various specialties, such as cardiology, urology, endoscopy, and neuromodulation. The company's commitment to research and development enables it to introduce advanced technologies and therapies that address unmet clinical needs. Boston Scientific Corp also focuses on collaborations and partnerships to expand its product portfolio, improve access to healthcare, and provide high-quality medical devices to patients worldwide.
Boston Scientific Corp is primarily active in the medical equipment and supplies industry.
Boston Scientific Corp is a renowned medical technology company based in Marlborough, Massachusetts. Established in 1979, it has become a global leader in the development, manufacturing, and marketing of innovative medical devices. With a focus on advancing patient care, Boston Scientific Corp offers a wide range of products for various medical specialties, including interventional cardiology, urology, endoscopy, and neuromodulation. The company's history showcases its commitment to medical breakthroughs and improving the lives of patients worldwide. Boston Scientific Corp's dedication to cutting-edge technology and strategic acquisitions has allowed it to maintain a prominent position in the healthcare industry.
Boston Scientific Corp has achieved significant milestones throughout its history. Some notable achievements include the development of the Taxus Express, a groundbreaking drug-eluting stent that revolutionized the treatment of coronary artery disease. Additionally, the acquisition of Guidant Corporation strengthened Boston Scientific's position in the field of cardiac rhythm management. The company's innovative products, such as the Watchman Left Atrial Appendage Closure device, have provided improved treatment options for patients with atrial fibrillation. Boston Scientific Corp continues to innovate and make advancements in medical technologies, helping to improve patient outcomes worldwide.
Boston Scientific Corp is primarily present in several countries and regions worldwide. The company has a strong global presence, with significant operations in the United States, Europe, Asia-Pacific, Latin America, and the Middle East. Its diverse market reach spans across more than 130 countries, enabling Boston Scientific Corp to provide innovative medical solutions and technologies to a vast range of patients and healthcare professionals worldwide.
Boston Scientific Corp represents values of innovation, collaboration, and patient-centricity. With a strong corporate philosophy focused on improving patients' lives, the company is committed to developing and delivering innovative medical solutions. Boston Scientific Corp's dedication to collaboration extends to its partnerships with healthcare professionals and institutions, helping to address unmet needs and improve patient outcomes. By prioritizing patient-centric care, the company ensures that its products and services are designed to provide effective and meaningful treatments. Boston Scientific Corp's continued commitment to innovation and collaboration underscores its mission to transform lives through medical advancements in a rapidly evolving healthcare landscape.
Analysts currently set an average price target of 66.50 USD for the Boston Scientific stock (median: 63.50 USD), implying +56.1 % versus the latest price. The consensus is based on 38 analyst ratings.
38 analysts currently rate the Boston Scientific stock: 30 recommend buying, 8 holding and 0 selling. For 2026, analysts expect Boston Scientific to generate revenue of 21.25 B USD and earnings per share of 3.24 USD.
Converted at the current exchange rate, the Boston Scientific share trades at 37.87 EUR (42.60 USD).
The Boston Scientific share (BSX) is listed on 10 stock exchanges, including: NYSE (BSX), London (0HOY.L), SIX (Zürich) (BSX.SW), XETRA (BSX.DE), Frankfurt (BSX.F), München (BSX.MU), Düsseldorf (BSX.DU), Wien (BSXC.VI).
The Boston Scientific Corporation is a medical technology company that specializes in the manufacturing and development of medical devices. The company was founded in Massachusetts in 1979 and operates globally today. Its business model includes various divisions that focus on different medical specialties. The Cardiac Rhythm Management division of Boston Scientific is involved in the manufacturing of devices for the treatment of heart rhythm disorders. This includes products such as implantable defibrillators, pacemakers, and accessories. The products in this division are of high quality and have an excellent track record in treating patients with severe heart problems. The Interventional Cardiology division of Boston Scientific specializes in the manufacturing of products used in the treatment of heart diseases. This includes balloon catheters, stents, and catheter ablation systems. These products are typically minimally invasive and allow for a quick restoration of normal heart rhythm in patients. The Interventional Radiology division of Boston Scientific is focused on the manufacturing of products for the diagnosis and treatment of vascular diseases. The company produces catheters, stents, and embolization accessories, among other things. Additionally, Boston Scientific is also specialized in the development of products for the treatment of chronic pain. The products in this division include implantable pain therapy systems, neurostimulators, and accessories. These devices can alleviate patients' pain and improve their quality of life. The company is also specialized in the field of urology, including products for the treatment of conditions such as urinary incontinence and benign prostatic hyperplasia. Boston Scientific produces mesh implants and devices aimed at improving bladder control. Furthermore, the company has a division dedicated to gastrointestinal diseases, including products for the treatment of conditions like colorectal cancer and gastrointestinal bleeding. The portfolio includes endoscopes, balloon catheters, and other devices for the treatment of digestive tract disorders. Boston Scientific is committed to providing its customers with the best products. Product development is strongly focused on meeting the needs of patients and doctors. By continually developing new products, the company can expand its market position and maintain its leading position in the medical technology industry.
The expected revenue of Boston Scientific is 21.25 B USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Boston Scientific is 4.85 B USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Boston Scientific is currently 13.13. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Boston Scientific stock.
The price-to-sales ratio (P/S) of Boston Scientific is currently 3.00. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Boston Scientific stock.
The Eulerpool Quality Score for Boston Scientific is 5/10.
The ISIN of Boston Scientific is US1011371077. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Boston Scientific is 884113. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Boston Scientific is BSX. The ticker symbol is used to trade Boston Scientific shares on the stock exchange.
Boston Scientific stock
Boston Scientific Peer Group
Boston Scientific Ticker
Boston Scientific FIGI
All fundamentals and in-depth analysis of Boston Scientific
Our stock analysis for Boston Scientific stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Boston Scientific. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.